Estudios Clínicos Latino América
Quick facts
Phase 3 pipeline
- Icosapent ethyl (IPE) · Cardiovascular
Icosapent ethyl is a purified ethyl ester of eicosapentaenoic acid (EPA) that reduces triglyceride levels and modulates lipid metabolism.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Estudios Clínicos Latino América portfolio CI brief
- Estudios Clínicos Latino América pipeline updates RSS
Frequently asked questions about Estudios Clínicos Latino América
What is Estudios Clínicos Latino América's pipeline?
Estudios Clínicos Latino América has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Icosapent ethyl (IPE).
Related
- Sector hub: All tracked pharma companies